Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.Invivoscribe Marketing2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases| Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic MalignanciesInvivoscribe Marketing2021-02-26T19:10:45-08:00May 21st, 2019|2019 Press Releases, Press Releases| Read more
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2021-02-26T19:14:37-08:00March 28th, 2016|2016 Press Releases, Press Releases| Read more